PDS Biotechnology (NASDAQ:PDSB) Receives “Buy” Rating from HC Wainwright

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports.

Several other research firms have also issued reports on PDSB. Weiss Ratings raised shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. Wall Street Zen raised shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, PDS Biotechnology presently has an average rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Stock Up 2.2%

NASDAQ:PDSB opened at $0.22 on Wednesday. The firm has a market capitalization of $12.40 million, a price-to-earnings ratio of -0.35 and a beta of 1.62. PDS Biotechnology has a twelve month low of $0.20 and a twelve month high of $1.55. The stock’s 50 day moving average price is $0.67 and its two-hundred day moving average price is $0.82. The company has a quick ratio of 0.57, a current ratio of 0.57 and a debt-to-equity ratio of 2.73.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Equities research analysts expect that PDS Biotechnology will post -0.47 earnings per share for the current fiscal year.

Institutional Trading of PDS Biotechnology

A number of hedge funds have recently made changes to their positions in the business. Virtu Financial LLC acquired a new position in shares of PDS Biotechnology during the 4th quarter worth approximately $25,000. Marshall Wace LLP bought a new stake in PDS Biotechnology in the 2nd quarter valued at $91,000. Bank of New York Mellon Corp acquired a new stake in PDS Biotechnology during the 2nd quarter valued at $60,000. Jane Street Group LLC acquired a new stake in PDS Biotechnology during the 2nd quarter valued at $92,000. Finally, Susquehanna International Group LLP boosted its position in PDS Biotechnology by 603.7% during the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after purchasing an additional 80,937 shares during the period. 26.84% of the stock is owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.